Eggermont Am
Impact in
-
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
-
- Immunotherapy and Immune Responses
Papers in
- Oncology 8
- Cutaneous Melanoma Detection and Management 5
- Cancer Immunotherapy and Biomarkers 2
- CAR-T cell therapy research 2
-
- Immune Cell Function and Interaction 4
- Co-authors
- Kroon Bb (4 shared papers)F. Rosenkaimer (1 shared paper)Philippe Autier (1 shared paper)D. Liénard (1 shared paper)Sugarbaker Ph (2 shared papers)Ulrich Keilholz (2 shared papers)J Jeekel (1 shared paper)Alan Spatz (1 shared paper)
- Journals
- The Lancet (1 paper)British Journal of Cancer (1 paper)PubMed (10 papers)
- Partner nations
- United StatesNetherlands
In The Last Decade
Eggermont Am
12 papers receiving 321 citations
Peers
Comparison fields: 5 of 43
- Oncology 197
- Immunology 70
- Immunology and Allergy 14
- Biological Psychiatry 5
- Dermatology 11
Countries citing papers authored by Eggermont Am
This map shows the geographic impact of Eggermont Am's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eggermont Am with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eggermont Am more than expected).
Fields of papers citing papers by Eggermont Am
This network shows the impact of papers produced by Eggermont Am. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eggermont Am. The network helps show where Eggermont Am may publish in the future.
Co-authors
The 25 scholars most cited alongside Eggermont Am, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. | 1994 | 87 |
| 2 | EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. | 2008 | 79 |
| 3 | Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. | 1994 | 53 |
| 4 | Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells. | 1988 | 51 |
| 5 | Phase II trial of high-dose recombinant leukocyte alpha-2 interferon for metastatic colorectal cancer without previous systemic treatment. | 1985 | 17 |
| 6 | The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. | 2000 | 11 |
| 7 | Regional application of TNF alpha in the treatment of cancer: a preclinical-clinical interactive program. | 1997 | 11 |
| 8 | 1987 | 9 | |
| 9 | Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs? | 1994 | 7 |
| 10 | Regional isolated perfusion with melphalan for patients with subungual melanoma. | 1993 | 6 |
| 11 | Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon. | 1992 | 2 |
| 12 | Efficacy of intracavitary administration of cyclophosphamide, interleukin-2 and lymphokine activated killer cells against established intraperitoneal tumor. | 1989 | 2 |
About Eggermont Am
Eggermont Am is a scholar working on Oncology, Immunology, Molecular Biology, Surgery and Nephrology, having authored 12 papers that have together received 335 indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (5 papers), Immune Cell Function and Interaction (4 papers), Melanoma and MAPK Pathways (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), CAR-T cell therapy research (2 papers), Intraperitoneal and Appendiceal Malignancies (1 paper), Microbial Inactivation Methods (1 paper) and Optical Coherence Tomography Applications (1 paper). The work is most often cited by research in Oncology (197 citations), Immunology (70 citations), Immunology and Allergy (14 citations), Biological Psychiatry (5 citations) and Dermatology (11 citations). Eggermont Am has collaborated with scholars based in United States and Netherlands. Frequent co-authors include Kroon Bb, F. Rosenkaimer, Philippe Autier, D. Liénard, Sugarbaker Ph, Ulrich Keilholz, J Jeekel, Alan Spatz, M. Gore and E. Musat. Their work appears in journals such as The Lancet, British Journal of Cancer and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.